Pharma Mar Förvaltning
Förvaltning kriterier kontrolleras 2/4
Pharma Mar VD är Jose Fernandez Sousa-Faro, utsedd i Jan 1986, har en anställningstid på 40.33 år. äger direkt 6.43% av företagets aktier, värda € 113.33M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 15.2 år respektive 3.9 år.
Viktig information
Jose Fernandez Sousa-Faro
Verkställande direktör
n/a
Total ersättning
| VD-lön i procent | n/a |
| Anställning som VD | 40.3yrs |
| Ägande av VD | 6.4% |
| Ledningens genomsnittliga anställningstid | 15.2yrs |
| Styrelsens genomsnittliga mandatperiod | 3.9yrs |
Senaste uppdateringar av ledningen
Recent updates
Uppdatering av berättelse • May 21
PHM: Asia Pacific Lung Cancer Expansion Will Support Medium Term Upside Potential
Analysts have raised their price target on Pharma Mar from €118 to €125, citing new research that reflects updated assumptions on growth, profitability and future P/E expectations following fresh coverage with a bullish stance. Analyst Commentary Recent Street research coverage reflects a confident tone around Pharma Mar, with bullish analysts pointing to updated assumptions on growth, profitability and future P/E expectations as key supports for higher valuation ranges.Analysartikel • May 09
Pharma Mar's (BME:PHM) Solid Profits Have Weak Fundamentals
Despite posting some strong earnings, the market for Pharma Mar, S.A.'s ( BME:PHM ) stock hasn't moved much. We did...Analysartikel • Nov 07
There May Be Underlying Issues With The Quality Of Pharma Mar's (BME:PHM) Earnings
Pharma Mar, S.A.'s ( BME:PHM ) robust earnings report didn't manage to move the market for its stock. We did some...Analysartikel • Nov 02
Pharma Mar, S.A. (BME:PHM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Pharma Mar, S.A. ( BME:PHM ) last week reported its latest third-quarter results, which makes it a good time for...Analysartikel • Oct 29
Is Pharma Mar (BME:PHM) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Aug 03
Risks To Shareholder Returns Are Elevated At These Prices For Pharma Mar, S.A. (BME:PHM)
It's not a stretch to say that Pharma Mar, S.A.'s ( BME:PHM ) price-to-sales (or "P/S") ratio of 7.4x right now seems...Analysartikel • Jun 16
Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.80
Pharma Mar, S.A.'s ( BME:PHM ) dividend will be increasing from last year's payment of the same period to €0.80 on 27th...Analysartikel • May 23
Pharma Mar (BME:PHM) Has Announced That It Will Be Increasing Its Dividend To €0.80
Pharma Mar, S.A. ( BME:PHM ) will increase its dividend from last year's comparable payment on the 27th of June to...
Ny berättelse • Mar 09
ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe
Successful approval of ZEPZELCA in Europe and new markets could significantly boost PharmaMar’s future revenues, leveraging positive trial results.Analysartikel • Mar 06
We Think Shareholders Should Be Aware Of Some Factors Beyond Pharma Mar's (BME:PHM) Profit
The latest earnings release from Pharma Mar, S.A. ( BME:PHM ) disappointed investors. Our analysis found several...Analysartikel • Feb 13
There's Reason For Concern Over Pharma Mar, S.A.'s (BME:PHM) Massive 27% Price Jump
The Pharma Mar, S.A. ( BME:PHM ) share price has done very well over the last month, posting an excellent gain of 27...Analysartikel • Oct 16
Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%
Pharma Mar, S.A. ( BME:PHM ) shares have continued their recent momentum with a 55% gain in the last month alone. The...Analysartikel • Jul 28
Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Pharma Mar, S.A. ( BME:PHM ) shares have continued their recent momentum with a 27% gain in the last month alone...Analysartikel • Jun 01
Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65
Pharma Mar, S.A.'s ( BME:PHM ) dividend will be increasing from last year's payment of the same period to €0.65 on 14th...Analysartikel • May 28
Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry
Pharma Mar, S.A. ( BME:PHM ) shareholders would be excited to see that the share price has had a great month, posting a...Analysartikel • Mar 03
Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Last week, you might have seen that Pharma Mar, S.A. ( BME:PHM ) released its annual result to the market. The early...Analysartikel • Jan 25
Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Apr 28
Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Pharma Mar fair value estimate is €52.37 Pharma Mar is...Analysartikel • Mar 08
We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability
Pharma Mar, S.A.'s ( BME:PHM ) lackluster earnings announcement last week disappointed investors. We think that they...Analysartikel • Mar 05
Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)
Market forces rained on the parade of Pharma Mar, S.A. ( BME:PHM ) shareholders today, when the analysts downgraded...Analysartikel • Feb 09
Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Oct 27
We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysartikel • Sep 27
An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued
Today we will run through one way of estimating the intrinsic value of Pharma Mar, S.A. ( BME:PHM ) by estimating the...VD OCH KONCERNCHEF
Jose Fernandez Sousa-Faro
40.3yrs
Anställning
€294,000
Kompensation
Mr. José María Fernández Sousa-Faro, Ph D., founded Pharma Mar, S.A.U. in 1986. He Founded Noscira, S.A., in 2000.He serves as the Chief Executive Officer and President of Pharma Mar, S.A.U. He serves as...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Founder | 40.3yrs | €294.00k | 6.43% € 113.3m | |
| Executive Vice-Chairman | no data | €124.00k | 0.00058% € 10.2k | |
| Founder | no data | inga uppgifter | inga uppgifter | |
| Chief Financial Officer | 26.3yrs | inga uppgifter | inga uppgifter | |
| Head of Capital Markets & Investor Relations | 11.3yrs | inga uppgifter | inga uppgifter | |
| General Counsel & Secretary of the Board of Directors | 6.7yrs | inga uppgifter | inga uppgifter | |
| Global Compliance Head | 6yrs | inga uppgifter | inga uppgifter | |
| Communication Director | no data | inga uppgifter | inga uppgifter | |
| Director of Corporate Development | 4.3yrs | inga uppgifter | inga uppgifter | |
| Director of Human Resources & IT | 22.8yrs | inga uppgifter | inga uppgifter | |
| Managing Director of Oncology & Virology Business Units | 19.1yrs | inga uppgifter | inga uppgifter | |
| Senior Vice President of Strategic Development | no data | inga uppgifter | inga uppgifter |
15.2yrs
Genomsnittlig anställningstid
Erfaren ledning: PHM s ledningsgrupp är erfaren och erfaren ( 15.2 års genomsnittlig anställning).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Founder | no data | €294.00k | 6.43% € 113.3m | |
| Executive Vice-Chairman | no data | €124.00k | 0.00058% € 10.2k | |
| Independent Other External Director | 5.3yrs | €35.00k | 0.062% € 1.1m | |
| Independent Other External Director | no data | €35.00k | inga uppgifter | |
| Proprietary Director | no data | €34.00k | 5.51% € 97.1m | |
| Independent Director | 7.3yrs | inga uppgifter | 0.010% € 182.7k | |
| Representative Proprietary Director | 5.4yrs | inga uppgifter | inga uppgifter | |
| Independent Director | 3.9yrs | inga uppgifter | 0.010% € 182.7k | |
| Independent Coordinating Director | 3.9yrs | inga uppgifter | inga uppgifter | |
| Independent Director | 3.9yrs | inga uppgifter | inga uppgifter | |
| Independent Other External Director | no data | inga uppgifter | 0.010% € 182.7k | |
| Independent Director | 3yrs | inga uppgifter | inga uppgifter |
3.9yrs
Genomsnittlig anställningstid
Erfaren styrelse: PHM s styrelse anses vara erfaren ( 3.9 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/25 05:20 |
| Aktiekurs vid dagens slut | 2026/05/25 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Pharma Mar, S.A. bevakas av 12 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Jaime Escribano | Banco Santander |
| Patricia Cifuentes | Bestinver Sociedad De Valores, S.A |
| Kambiz Yazdi | BTIG |